Compare OII & PBLS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | OII | PBLS |
|---|---|---|
| Founded | 1964 | N/A |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Oilfield Services/Equipment | Biotechnology: Pharmaceutical Preparations |
| Sector | Energy | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 4.0B | 3.4B |
| IPO Year | 1994 | 2026 |
| Metric | OII | PBLS |
|---|---|---|
| Price | $38.13 | $29.40 |
| Analyst Decision | Hold | |
| Analyst Count | 3 | 0 |
| Target Price | ★ $31.33 | N/A |
| AVG Volume (30 Days) | ★ 1.1M | 616.6K |
| Earning Date | 04-22-2026 | N/A |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 142.36 | N/A |
| EPS | ★ 0.36 | N/A |
| Revenue | ★ $2,784,156,000.00 | N/A |
| Revenue This Year | $2.83 | N/A |
| Revenue Next Year | $5.34 | N/A |
| P/E Ratio | $106.94 | ★ N/A |
| Revenue Growth | ★ 4.62 | N/A |
| 52 Week Low | $20.63 | $25.56 |
| 52 Week High | $41.15 | $30.19 |
| Indicator | OII | PBLS |
|---|---|---|
| Relative Strength Index (RSI) | 50.92 | 62.69 |
| Support Level | $34.38 | $25.70 |
| Resistance Level | $39.82 | $30.19 |
| Average True Range (ATR) | 1.61 | 2.36 |
| MACD | 0.18 | 0.15 |
| Stochastic Oscillator | 58.27 | 86.83 |
Oceaneering International Inc is a provider of engineered services and products and robotic solutions to the offshore energy, defense, aerospace, manufacturing, and entertainment industries. A majority of its products are produced for the offshore oil and gas market. The company's business segments are Integrity Management and Digital Solutions, Subsea Robotics, Manufactured Products, Offshore Projects Group, and Aerospace and Defense Technologies. Maximum revenue is generated from its Subsea Robotics segment, which provides remotely operated vehicles (ROVs) for drill support and vessel-based services, underwater surveys, tooling, and other activities. Geographically, the company derives its key revenue from the United States, followed by Africa, Norway, Brazil, and other regions.
Parabilis Medicines Inc s a clinical-stage biopharmaceutical company. It is focused on the development of medicines targeting protein interactions associated with human diseases. It uses a proprietary platform to develop stabilized helical peptide therapeutics, referred to as Helicons, designed to bind and modulate specific proteins. Its flagship product candidate, zolucatetide, targets the interaction between β-catenin and the T-cell factor (TCF) family of transcription factors within the Wnt/β-catenin signaling pathway, which is associated with cell proliferation and differentiation in multiple cancer types.